دورية أكاديمية
Synthesis, characterization, and antibacterial activities of a heteroscorpionate derivative platinum complex against methicillin-resistant Staphylococcus aureus .
| العنوان: | Synthesis, characterization, and antibacterial activities of a heteroscorpionate derivative platinum complex against methicillin-resistant Staphylococcus aureus . |
|---|---|
| المؤلفون: | Nam-Cha SH; Department of Pathology, Complejo Hospitalario Universitario, Albacete, Spain., Domínguez-Jurado E; Departamento de Química Inorgánica, Orgánica y Bioquímica-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Facultad de Farmacia, Universidad de Castilla-La Mancha, Albacete, Spain.; Unidad nanoDrug, Centro Regional de Investigación Biomédicas, Universidad de Castilla-La Mancha, Albacete, Spain., Tinoco-Valencia SL; Clinical Microbiology Department, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain., Pérez-Tanoira R; Clinical Microbiology Department, Hospital Universitario Príncipe de Asturias, Madrid, Spain.; Biomedicine y Biotechnology Department, School of Medicine, University of Alcalá de Henares, Alcalá de Henares, Spain., Morata-Moreno N; Department of Otorrinolaringology, Complejo Hospitalario Universitario, Albacete, Spain., Alfaro-Ruiza R; Instituto de Investigación en Discapacidades Neurológicas (IDINE), University of Castilla-La Mancha, Albacete, Spain., Lara-Sánchez A; Departamento de Química Inorgánica, Orgánica y Bioquímica-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Facultad de Farmacia, Universidad de Castilla-La Mancha, Albacete, Spain., Esteban J; Clinical Microbiology Department, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain.; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Luján R; Instituto de Investigación en Discapacidades Neurológicas (IDINE), University of Castilla-La Mancha, Albacete, Spain., Alonso-Moreno C; Departamento de Química Inorgánica, Orgánica y Bioquímica-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Facultad de Farmacia, Universidad de Castilla-La Mancha, Albacete, Spain.; Unidad nanoDrug, Centro Regional de Investigación Biomédicas, Universidad de Castilla-La Mancha, Albacete, Spain., Seguí P; Department of Otorrinolaringology, Complejo Hospitalario Universitario, Albacete, Spain.; Instituto de Investigación en Discapacidades Neurológicas (IDINE), University of Castilla-La Mancha, Albacete, Spain., Ocaña A; Experimental Therapeutics Unit, Hospital Clínico San Carlos, IdISSC and CIBERONC, Madrid, Spain.; Translational Research Unit, Albacete University Hospital, Albacete, Spain., Gónzalez ÁL; Department of Nursing, University of Castilla-La Mancha, Albacete, Spain., Aguilera-Correa JJ; Clinical Microbiology Department, IIS-Fundacion Jimenez Diaz-UAM, Madrid, Spain.; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Pérez-Martínez FC; Instituto de Investigación en Discapacidades Neurológicas (IDINE), University of Castilla-La Mancha, Albacete, Spain.; Department of Nursing, University of Castilla-La Mancha, Albacete, Spain., Alarcón MM; Instituto de Investigación en Discapacidades Neurológicas (IDINE), University of Castilla-La Mancha, Albacete, Spain.; Department of Nursing, University of Castilla-La Mancha, Albacete, Spain. |
| المصدر: | Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2023 Mar 27; Vol. 13, pp. 1100947. Date of Electronic Publication: 2023 Mar 27 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media SA |
| مواضيع طبية MeSH: | Methicillin-Resistant Staphylococcus aureus*, Staphylococcus aureus ; Platinum/pharmacology ; Anti-Bacterial Agents/pharmacology ; Methicillin/pharmacology ; Microbial Sensitivity Tests ; Biofilms |
| مستخلص: | Staphylococcus aureus is one of the species with the greatest clinical importance and greatest impact on public health. In fact, methicillin-resistant S. aureus (MRSA) is considered a pandemic pathogen, being essential to develop effective medicines and combat its rapid spread. This study aimed to foster the translation of clinical research outcomes based on metallodrugs into clinical practice for the treatment of MRSA. Bearing in mind the promising anti-Gram-positive effect of the heteroscorpionate ligand 1,1'-(2-(4-isopropylphenyl)ethane-1,1-diyl)bis(3,5-dimethyl-1H-pyrazole) (2P), we propose the coordination of this compound to platinum as a clinical strategy with the ultimate aim of overcoming resistance in the treatment of MRSA. Therefore, the novel metallodrug 2P-Pt were synthetized, fully characterized and its antibacterial effect against the planktonic and biofilm state of S. aureus evaluated. In this sense, three different strains of S. aureus were studied, one collection strain of S. aureus sensitive to methicillin and two clinical MRSA strains. To appraise the antibacterial activity, minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), minimum biofilm inhibitory concentration (MBIC), and minimum biofilm eradication concentration (MBEC) were determined. Moreover, successful outcomes on the development of biofilm in a wound-like medium were obtained. The mechanism of action for 2P-Pt was proposed by measuring the MIC and MBC with EDTA (cation mediated mechanism) and DMSO (exogenous oxidative stress mechanism). Moreover, to shed light on the plausible antistaphylococcal mechanism of this novel platinum agent, additional experiments using transmission electron microscopy were carried out. 2P-Pt inhibited the growth and eradicated the three strains evaluated in the planktonic state. Another point worth stressing is the inhibition in the growth of MRSA biofilm even in a wounded medium. The results of this work support this novel agent as a promising therapeutic alternative for preventing infections caused by MRSA. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Nam-Cha, Domínguez-Jurado, Tinoco-Valencia, Pérez-Tanoira, Morata-Moreno, Alfaro-Ruiza, Lara-Sánchez, Esteban, Luján, Alonso-Moreno, Seguí, Ocaña, Gónzalez, Aguilera-Correa, Pérez-Martínez and Alarcón.) |
| References: | Future Microbiol. 2007 Jun;2(3):323-34. (PMID: 17661706) Small. 2015 Jan 7;11(1):26-44. (PMID: 25303765) Antibiotics (Basel). 2021 Dec 03;10(12):. (PMID: 34943693) Clin Microbiol Rev. 2015 Jul;28(3):603-61. (PMID: 26016486) Clin Microbiol Infect. 2012 Mar;18(3):268-81. (PMID: 21793988) J Am Heart Assoc. 2022 Mar 15;11(6):e024648. (PMID: 35229619) Antibiotics (Basel). 2018 Oct 26;7(4):. (PMID: 30373130) Acta Biomater. 2022 Jan 1;137:218-237. (PMID: 34653694) Genome Announc. 2014 Nov 06;2(6):. (PMID: 25377701) Eur J Med Chem. 2015 Aug 28;101:534-51. (PMID: 26188909) Chem Sci. 2020 Feb 12;11(10):2627-2639. (PMID: 32206266) APMIS. 2007 Aug;115(8):891-9. (PMID: 17696944) Cell Microbiol. 2012 Oct;14(10):1513-21. (PMID: 22747834) Molecules. 2020 Nov 12;25(22):. (PMID: 33198217) Nat Prod Rep. 2021 Apr 28;38(4):782-821. (PMID: 33119013) Sci Rep. 2013;3:1260. (PMID: 23405274) Medchemcomm. 2017 Dec 20;9(2):282-298. (PMID: 30108922) Adv Wound Care (New Rochelle). 2015 Jul 1;4(7):415-421. (PMID: 26155384) Clin Infect Dis. 2021 Oct 5;73(7):e1518-e1524. (PMID: 32818963) Curr Med Chem. 2019;26(41):7452-7475. (PMID: 30215328) Bioact Mater. 2021 May 08;6(12):4470-4490. (PMID: 34027235) Curr Opin Infect Dis. 2008 Aug;21(4):385-92. (PMID: 18594291) Pharmaceutics. 2019 Jan 14;11(1):. (PMID: 30646534) Nat Rev Microbiol. 2004 Feb;2(2):95-108. (PMID: 15040259) Magn Reson Chem. 2009 Nov;47(11):932-41. (PMID: 19691018) N Engl J Med. 1998 Aug 20;339(8):520-32. (PMID: 9709046) Materials (Basel). 2017 Aug 15;10(8):. (PMID: 28809799) Microb Pathog. 2018 Oct;123:339-347. (PMID: 30057355) Int J Mol Sci. 2022 May 12;23(10):. (PMID: 35628218) Nat Rev Microbiol. 2010 Sep;8(9):623-33. (PMID: 20676145) J Travel Med. 2019 Dec 23;26(8):. (PMID: 31115466) Eur Cell Mater. 2002 Dec 31;4:39-60. (PMID: 14562246) Drug Des Devel Ther. 2017 Mar 03;11:599-616. (PMID: 28424538) ChemMedChem. 2011 Jul 4;6(7):1172-83. (PMID: 21630470) Sci Total Environ. 2004 Jan 5;318(1-3):1-43. (PMID: 14654273) Dalton Trans. 2013 Mar 7;42(9):3196-209. (PMID: 23233164) J Environ Sci Health A Tox Hazard Subst Environ Eng. 2006;41(3):397-414. (PMID: 16484072) Antibiotics (Basel). 2022 Nov 17;11(11):. (PMID: 36421289) Theriogenology. 2021 Feb;161:219-227. (PMID: 33340755) Trends Microbiol. 2019 Jun;27(6):497-507. (PMID: 30846311) Pharmaceuticals (Basel). 2010 May 26;3(6):1711-1728. (PMID: 27713325) Medchemcomm. 2019 Mar 14;10(8):1231-1241. (PMID: 31534648) Photochem Photobiol. 2009 Sep-Oct;85(5):1177-81. (PMID: 19508643) Cell Rep. 2022 Jan 11;38(2):110202. (PMID: 35021083) Nat Rev Drug Discov. 2003 Feb;2(2):114-22. (PMID: 12563302) Nat Rev Cancer. 2021 Jan;21(1):37-50. (PMID: 33128031) Burns. 2017 Feb;43(1):50-57. (PMID: 27576926) Biology (Basel). 2022 Jan 20;11(2):. (PMID: 35205029) Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jun 15;163:1-7. (PMID: 27002605) Virulence. 2021 Dec;12(1):547-569. (PMID: 33522395) J Am Chem Soc. 2017 Oct 11;139(40):14143-14149. (PMID: 28901758) J Antimicrob Chemother. 1989 Sep;24(3):281-93. (PMID: 2681115) Food Chem Toxicol. 2021 Jul;153:112259. (PMID: 33984423) Sci Rep. 2021 Aug 11;11(1):16306. (PMID: 34381091) Antimicrob Agents Chemother. 2008 Aug;52(8):2870-81. (PMID: 18519726) Laryngoscope Investig Otolaryngol. 2022 Jan 18;7(1):283-290. (PMID: 35155809) Eur J Med Chem. 2018 Jul 15;155:459-482. (PMID: 29908440) Infect Drug Resist. 2019 Dec 20;12:3903-3910. (PMID: 31908502) |
| فهرسة مساهمة: | Keywords: MRSA; Staphycoccus aureus; biofilm; metallodrug; platinum |
| المشرفين على المادة: | 49DFR088MY (Platinum) 0 (Anti-Bacterial Agents) Q91FH1328A (Methicillin) |
| تواريخ الأحداث: | Date Created: 20230413 Date Completed: 20230414 Latest Revision: 20230415 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC10083354 |
| DOI: | 10.3389/fcimb.2023.1100947 |
| PMID: | 37051297 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2235-2988 |
|---|---|
| DOI: | 10.3389/fcimb.2023.1100947 |